Renaissance Technologies LLC Has $917,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Renaissance Technologies LLC boosted its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 435.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 157,300 shares of the company's stock after purchasing an additional 127,900 shares during the quarter. Renaissance Technologies LLC owned 0.27% of Olema Pharmaceuticals worth $917,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its stake in Olema Pharmaceuticals by 6.0% in the 4th quarter. Vanguard Group Inc. now owns 2,685,009 shares of the company's stock worth $15,654,000 after purchasing an additional 152,117 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in Olema Pharmaceuticals by 12.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company's stock worth $10,980,000 after purchasing an additional 215,895 shares in the last quarter. Candriam S.C.A. raised its stake in Olema Pharmaceuticals by 3.0% in the 4th quarter. Candriam S.C.A. now owns 1,551,562 shares of the company's stock worth $9,046,000 after purchasing an additional 44,798 shares in the last quarter. Wellington Management Group LLP raised its stake in Olema Pharmaceuticals by 52.1% in the 4th quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock worth $8,839,000 after purchasing an additional 522,799 shares in the last quarter. Finally, Schroder Investment Management Group raised its stake in Olema Pharmaceuticals by 548.7% in the 4th quarter. Schroder Investment Management Group now owns 533,111 shares of the company's stock worth $2,991,000 after purchasing an additional 450,924 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Analysts Set New Price Targets

OLMA has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, March 28th. Oppenheimer reissued an "outperform" rating and issued a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday.

Olema Pharmaceuticals Stock Up 2.4 %

OLMA stock opened at $5.16 on Thursday. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $16.62. The firm has a market cap of $352.60 million, a P/E ratio of -2.36 and a beta of 2.10. The company's 50-day moving average price is $4.19 and its two-hundred day moving average price is $6.71.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.12. Equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.